Equitable Trust’s Core Laboratories CLB Stock Holding History

Equitable Trust’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-19,000	Closed	-$1.31M	–	279
2019 Q1	$1.31M	Sell	19,000 -9,955	-34%	-$667K	0.15%	130
2018 Q4	$1.73M	Sell	28,955 -765	-3%	-$66K	0.23%	106
2018 Q3	$3.44M	Sell	29,720 -384	-1%	-$43.3K	0.4%	74
2018 Q2	$3.8M	Buy	+30,104	New	+$3.66M	0.48%	67

Other funds holding CLB

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Equitable Trust's CLB Position: Q2 2019 in Review

Equitable Trust sold out of Core Laboratories (CLB) in Q2 2019, closing a stake of 19,000 shares — an estimated $1.31M sold.

Equitable Trust first reported a position in CLB in Q2 2018 and held it in 4 quarters. The position peaked at $3.8M in Q2 2018. 304 funds tracked by Wall St. Rank hold CLB as of Q2 2019.

Equitable Trust reported no remaining Core Laboratories position as of Q2 2019 after selling out during the quarter.
Equitable Trust sold 19,000 Core Laboratories shares in Q2 2019, an estimated $1.31M.
Equitable Trust first reported a position in Core Laboratories in Q2 2018 and held it in 4 quarters.
Equitable Trust's Core Laboratories position peaked at $3.8M in Q2 2018.
304 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2019.

Based on Equitable Trust's 13F filing for Q2 2019, filed 16 Aug 2019.